サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793995

ヒドロキシジンの世界市場

Hydroxyzine

出版日
ページ情報
英文 284 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.30円
ヒドロキシジンの世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 284 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒドロキシジンの世界市場は2030年までに6億6,030万米ドルに達する見込み

2024年に5億1,680万米ドルと推定されるヒドロキシジンの世界市場は、2030年には6億6,030万米ドルに達し、分析期間2024-2030年のCAGRは4.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるヒスタミン介在性そう痒症は、CAGR 4.6%を記録し、分析期間終了時には3億8,780万米ドルに達すると予測されます。蕁麻疹適応症セグメントの成長率は、分析期間中CAGR 3.2%と推定されます。

米国市場は1億4,080万米ドルと推定、中国はCAGR 7.7％で成長すると予測

米国のヒドロキシジン市場は、2024年に1億4,080万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億3,560万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.3%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のヒドロキシジン市場- 主要動向と促進要因のまとめ

ヒドロキシジンが現代の治療プロトコルで広く処方されている理由とは？

ヒドロキシジンは、その多彩な薬理学的プロファイルにより、臨床医学の様々な分野で頻繁に使用される薬となっています。もともとは抗ヒスタミン薬として開発されましたが、ヒドロキシジンはその用途を広げ、現在ではアレルギー反応だけでなく、不安、吐き気、睡眠障害、そう痒症などにもよく処方されています。H1受容体拮抗作用と中枢神経抑制作用の両方を併せ持つため、複数の系統にまたがる症状の治療に効果的です。医師は、不安や興奮の短期的な緩和を必要とする患者、特に薬物乱用の既往があり従来の抗不安薬ではリスクが高い患者に対して、ベンゾジアゼピン系以外の選択肢としてヒドロキシジンを選択することが多いです。また、不安を和らげ、軽度の鎮静をもたらすために、術前設定でも一般的に処方されます。皮膚科領域では、ヒドロキシジンは、その鎮痒作用と慢性蕁麻疹や皮膚炎に関連した痒みに対処する能力から支持されています。さらに、制吐作用により、乗り物酔いや化学療法や術後の回復に関連した吐き気の治療にも有用です。ヒドロキシジンは、適応範囲が広く、中毒の危険性が比較的低いことから、外来および入院治療の定番となっています。経口剤と筋肉内投与剤があり、治療の緊急性や患者の経口服用能力に応じて柔軟に対応できます。小児科医も老人専門医も、ヒドロキシジンが適切な投与とモニタリングのもとで使用されるのであれば、価値あるツールであることを認めています。ヘルスケアプロバイダーは、規制薬物の複雑なリスクプロファイルを伴わずに複数の症状を緩和する薬剤を求めるようになってきており、ヒドロキシジンは治療計画における魅力的な選択肢であり続けています。

薬理学的特性と安全性プロファイルは、臨床的有用性にどのように影響するか？

ヒドロキシジンの薬理学的特性は、臨床医の間で現在も人気があることに重要な役割を果たしています。その最も顕著な特徴の一つは、血液脳関門を通過し、中枢神経系の活動を調節することによって鎮静効果を発揮する能力です。GABA受容体に直接作用する従来の鎮静剤や抗不安剤とは異なり、ヒドロキシジンはヒスタミン受容体に拮抗し、神経細胞の興奮性を低下させることで鎮静効果を発揮します。このユニークなメカニズムにより、ベンゾジアゼピン系抗不安薬にありがちな依存性や耐性の問題を起こすことなく、抗不安作用と鎮静作用を発揮します。本薬は作用発現が速く、通常、経口投与後15～30分以内に効果が現れるため、急性の不安エピソードやアレルギー反応に特に有用です。ヒドロキシジンは一般的に忍容性が高いが、特に肝障害または腎障害のある患者では、本剤が肝代謝され腎排泄されるため、一定の予防措置が必要です。眠気、口渇、めまい、時には目のかすみなどの副作用はよく見られますが、典型的には軽度で一過性のものです。重要なことは、ヒドロキシジンは他の鎮静剤と同程度には認知機能や運動機能を妨げないため、比較的注意力を保たなければならない患者にとって、より安全な選択肢であるということです。高用量または他の薬物との併用によりQT間隔延長の可能性があるため、既知の心臓疾患を有する患者には、心臓のモニタリングが推奨される場合があります。習慣性がないため、慢性的な症状管理が必要な長期療養環境において、その価値が高まる。全体として、ヒドロキシジンの確立された安全性プロファイル、幅広い作用スペクトラム、そして比較的安価であることが、現代臨床におけるその永続的な関連性に寄与しています。

世界のヘルスケアにおいて、どのような治療動向がヒドロキシジンの需要を形成していますか？

メンタルヘルスに対する認識、慢性疾患管理、多症候性治療における世界の動向は、すべてヒドロキシジンの持続的な需要に寄与しています。社会的ストレス、経済的不安定、パンデミック後のメンタルヘルスの課題により、不安障害の有病率が増加しているため、多くのヘルスケアプロバイダーは、多様な人々の症状を管理するために、即効性があり、依存性のない代替品を求めています。ヒドロキシジンはこの要求に合致し、誤用の心配が少ない症状緩和薬を提供します。同時に、鼻炎、湿疹、じんましんなどのアレルギー関連症状は、特に汚染レベルの高い都市環境において増加傾向にあります。ヒドロキシジンの抗ヒスタミン作用は、アレルギー症状のコントロールと、それに伴う不安や不眠の緩和の両方を必要とする患者に適した選択肢となります。腫瘍学や緩和ケアにおいて、ヒドロキシジンは吐き気、嘔吐、一般的な不快感を管理するための支持療法プロトコールにますます取り入れられています。ヒドロキシジンは、身体的、心理的な症状緩和の両面において有用であり、集学的治療計画における価値を高めています。さらに、ヒドロキシジンの適応外使用として、認知症や発達障害患者の興奮や過敏性など、特定の行動症状の治療が一般的になりつつあります。また、個別化医療や統合医療へのシフトの高まりは、臨床医に複数の症状に単一の化合物で対応する薬剤の採用を促し、ポリファーマシーのリスクを最小化しています。ヘルスケアシステムが費用対効果の高い幅広いスペクトルの薬剤に重点を置いているため、ヒドロキシジンはフォーミュラリーの対象として魅力的です。先進的な精神科治療薬や皮膚科治療薬へのアクセスが限られている多くの新興諸国では、ヒドロキシジンは信頼性が高く、手頃な価格の第一選択薬として役立っています。こうした広範な治療動向は、専門医療とプライマリ・ケアの両分野において、ヒドロキシジンの中核薬としての地位を確固たるものにしています。

世界のヒドロキシジン市場の継続的成長の要因は？

世界のヒドロキシジン市場は、臨床的有用性、手頃な価格、規制当局のサポート、先進国市場と新興国市場の両方におけるヘルスケア需要の増加などが相まって拡大しています。主な促進要因の一つは、精神疾患やアレルギー疾患の世界の負担の増大であり、迅速かつ安全に展開できる汎用性の高い治療オプションが必要とされています。ヒドロキシジンは、多面的なアプリケーションを備えており、患者が重複した症状を呈する複雑な症例を管理する開業医の間で支持を得ています。ヒドロキシジンは、特にジェネリック医薬品として手頃な価格であるため、公衆衛生システムや低資源環境において利用しやすい治療オプションとなっています。さらに、ヒドロキシジンは多くの国の規制当局によって広く承認されているため、政府が運営するヘルスケアプログラムおよび民間プロバイダーの両方を通じての流通が容易になっています。製薬会社は、進化する消費者の嗜好や臨床ニーズに対応するため、徐放バージョンや併用療法を含む新しい製剤への投資を続けています。遠隔医療やデジタル処方プラットフォームの台頭も一役買っており、ヒドロキシジンのように広く理解され、安全性の高い薬剤が遠隔処方によく選ばれています。病院や外来診療所では、ヒドロキシジンの効果が予測でき、他の治療法との相性も良いことから、治療プロトコルにヒドロキシジンを採用するケースが増えています。ポリファーマシーのリスクが高い小児医療や老人医療では、ヒドロキシジンの単剤有効性が重要な利点となっています。市場の成長は、メンタルヘルス治療に関連するスティグマ（偏見）を軽減することを目的とした教育イニシアティブによってさらに後押しされ、その結果、より多くの個人が不安、不眠、および関連する症状に対する医療支援を求めるようになっています。こうした要因の結果、ヒドロキシジンは世界的に安定した需要と市場浸透を続けており、包括的で利用しやすく費用対効果の高い薬理学的解決策に対するニーズの高まりにヘルスケアシステムが適応するにつれて、持続的な拡大が見込まれています。

セグメント

適応症タイプ（ヒスタミン介在性そう痒症適応症、じんま疹適応症、アトピー性接触皮膚炎適応症）、剤形（錠剤剤形、カプセル剤形、注射剤形、シロップ剤形）

調査対象企業の例

  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Ltd.
  • Lupin Limited
  • Mylan N.V.（Viatris）
  • Perrigo Company plc
  • Pfizer Inc.
  • Sandoz（a Novartis division）
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd.
  • Zydus Lifesciences Ltd.

AI統合

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37147

Global Hydroxyzine Market to Reach US$660.3 Million by 2030

The global market for Hydroxyzine estimated at US$516.8 Million in the year 2024, is expected to reach US$660.3 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Histamine-Mediated Pruritus Indication, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$387.8 Million by the end of the analysis period. Growth in the Urticaria Indication segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$140.8 Million While China is Forecast to Grow at 7.7% CAGR

The Hydroxyzine market in the U.S. is estimated at US$140.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$135.6 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Hydroxyzine Market - Key Trends and Drivers Summarized

Why Is Hydroxyzine a Widely Prescribed Medication in Modern Therapeutic Protocols?

Hydroxyzine has become a frequently utilized medication across various branches of clinical medicine due to its versatile pharmacological profile. Originally developed as an antihistamine, hydroxyzine has expanded in application and is now commonly prescribed not only for allergic reactions but also for anxiety, nausea, sleep disturbances, and pruritus. Its dual action as both an H1 receptor antagonist and a central nervous system depressant allows it to be effective in treating symptoms across multiple systems. Physicians often turn to hydroxyzine as a non-benzodiazepine alternative for patients who require short-term relief from anxiety or agitation, particularly those with a history of substance abuse where traditional anxiolytics may pose a higher risk. It is also commonly prescribed in preoperative settings to ease anxiety and produce mild sedation. In dermatology, hydroxyzine is favored for its antipruritic effects and ability to manage chronic urticaria and dermatitis-related itch. Furthermore, the medication’s antiemetic properties make it useful for treating motion sickness and nausea related to chemotherapy or postoperative recovery. The wide range of indications and relatively low risk of addiction has made hydroxyzine a staple in outpatient and inpatient care settings alike. Its oral and intramuscular formulations offer flexibility depending on the urgency of treatment or the patient’s ability to take medications orally. Pediatricians and geriatric specialists alike find hydroxyzine to be a valuable tool, provided it is used with appropriate dosing and monitoring. As healthcare providers increasingly look for medications that offer multi-symptom relief without the complex risk profiles of controlled substances, hydroxyzine remains an appealing choice in therapeutic planning.

How Do Pharmacological Properties and Safety Profiles Influence Its Clinical Utility?

The pharmacological characteristics of hydroxyzine play a significant role in its ongoing popularity among clinicians. One of its most notable features is its ability to cross the blood-brain barrier and exert calming effects through modulation of activity in the central nervous system. Unlike traditional sedatives or anxiolytics that directly affect GABA receptors, hydroxyzine exerts its calming influence by antagonizing histamine receptors and reducing neuronal excitability. This unique mechanism allows it to deliver anxiolytic and sedative effects without the typical dependence and tolerance issues that often accompany benzodiazepines. The drug has a rapid onset of action, typically taking effect within 15 to 30 minutes after oral administration, which is particularly useful in acute anxiety episodes or allergic reactions. While hydroxyzine is generally well tolerated, certain precautions are necessary, especially in patients with liver or kidney impairment, since the drug is metabolized hepatically and excreted renally. Side effects such as drowsiness, dry mouth, dizziness, and occasionally blurred vision are common but typically mild and transient. Importantly, hydroxyzine does not interfere with cognitive or motor functions to the same extent as other sedatives, making it a safer option for individuals who must remain relatively alert. Cardiac monitoring may be advised in patients with known heart conditions due to the potential for QT interval prolongation in high doses or when combined with other medications. Its non-habit-forming nature adds to its value in long-term care environments where chronic symptom management is necessary. Overall, hydroxyzine's well-established safety profile, broad spectrum of action, and relatively low cost contribute to its enduring relevance in modern clinical practice.

What Therapeutic Trends Are Shaping the Demand for Hydroxyzine in Global Healthcare?

Global trends in mental health awareness, chronic disease management, and multi-symptom therapy are all contributing to sustained demand for hydroxyzine. The increasing prevalence of anxiety disorders, driven by societal stress, economic instability, and post-pandemic mental health challenges, has led many healthcare providers to seek fast-acting, non-addictive alternatives to manage symptoms in diverse populations. Hydroxyzine fits this requirement, offering symptomatic relief with fewer concerns about misuse. At the same time, allergy-related conditions such as rhinitis, eczema, and hives are on the rise, particularly in urban environments with high pollution levels. The antihistamine properties of hydroxyzine make it a suitable option for patients requiring both allergic symptom control and relief from associated anxiety or insomnia. In oncology and palliative care settings, hydroxyzine is increasingly incorporated into supportive care protocols to manage nausea, vomiting, and general discomfort. Its dual utility in both physical and psychological symptom relief enhances its value in multidisciplinary treatment plans. Additionally, hydroxyzine’s off-label use in treating certain behavioral symptoms, including agitation and irritability in patients with dementia or developmental disorders, is becoming more common. The growing shift toward personalized and integrative medicine is also pushing clinicians to adopt medications that address multiple symptoms with a single compound, minimizing polypharmacy risks. With healthcare systems focusing on cost-effective, broad-spectrum medications, hydroxyzine remains attractive for formulary inclusion. In many developing countries, where access to advanced psychiatric or dermatologic drugs may be limited, hydroxyzine serves as a reliable and affordable first-line option. These broader therapeutic trends are helping solidify its position as a core medication in both specialty and primary care environments.

What Factors Are Contributing to the Continued Growth of the Hydroxyzine Market Globally?

The global hydroxyzine market is expanding due to a combination of clinical utility, affordability, regulatory support, and increasing healthcare demands across both developed and emerging markets. One major driver is the growing global burden of mental health conditions and allergic diseases, which require versatile treatment options that can be deployed quickly and safely. Hydroxyzine, with its multifaceted applications, has gained favor among practitioners who manage complex cases where patients present with overlapping symptoms. The affordability of hydroxyzine, particularly in its generic forms, makes it an accessible treatment option in public health systems and low-resource settings. Additionally, the widespread approval of hydroxyzine by regulatory bodies in numerous countries facilitates its distribution through both government-run healthcare programs and private providers. Pharmaceutical companies are continuing to invest in new formulations, including extended-release versions and combination therapies, to cater to evolving consumer preferences and clinical needs. The rise in telemedicine and digital prescribing platforms has also played a role, as medications like hydroxyzine that are widely understood and have a strong safety record are frequently chosen for remote prescriptions. Hospitals and outpatient clinics increasingly favor hydroxyzine in treatment protocols because of its predictable effects and compatibility with other therapies. In pediatric and geriatric care, where polypharmacy risks are higher, hydroxyzine’s single-agent efficacy is a key advantage. Market growth is further supported by educational initiatives aimed at reducing the stigma associated with mental health treatment, which in turn is encouraging more individuals to seek medical support for anxiety, insomnia, and related conditions. As a result of these factors, hydroxyzine continues to see steady demand and market penetration globally, with prospects for sustained expansion as healthcare systems adapt to the rising need for comprehensive, accessible, and cost-effective pharmacological solutions.

SCOPE OF STUDY:

The report analyzes the Hydroxyzine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication Type (Histamine-Mediated Pruritus Indication, Urticaria Indication, Atopic Contact Dermatitis Indication); Dosage Form (Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form, Syrup Dosage Form)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Ltd.
  • Lupin Limited
  • Mylan N.V. (Viatris)
  • Perrigo Company plc
  • Pfizer Inc.
  • Sandoz (a Novartis division)
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hydroxyzine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anxiety and Allergic Conditions Throws the Spotlight on Hydroxyzine as a Versatile Therapeutic Agent
    • Increased Preference for Non-Benzodiazepine Anxiolytics Propels Growth in Hydroxyzine Prescriptions
    • Here's the Story: Expanding Off-Label Use in Sleep Disorders and Itching Strengthens the Business Case for Hydroxyzine
    • Growing Demand for Pediatric Allergy Treatments Drives Adoption in Liquid and Syrup Formulations
    • Cost-Effective Generic Availability Sustains Widespread Use Across Primary Care and Psychiatry Settings
    • Integration into Multimodal Treatment Plans Enhances Demand in Dermatology and Palliative Care
    • Rising Incidence of Urticaria and Atopic Dermatitis Expands Addressable Market for Antihistamine-Based Therapies
    • Preference for Sedating Antihistamines in Acute Episodes Fuels Short-Term Use Cases for Hydroxyzine
    • Global Generic Drug Expansion and Local Manufacturing Capabilities Drive Accessibility in Emerging Markets
    • Formulation Innovations and Extended-Release Research Open Future Opportunities in Dosing Convenience
    • Telehealth and E-Prescription Models Support Continued Market Presence in Remote and Mental Health Care Settings
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hydroxyzine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Histamine-Mediated Pruritus Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Urticaria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Atopic Contact Dermatitis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tablets Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Capsules Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Injection Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Syrup Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • JAPAN
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • CHINA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • EUROPE
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • FRANCE
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • GERMANY
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • INDIA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • AFRICA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030

IV. COMPETITION